ODTX
Odyssey Therapeutics, Inc.
Price Chart
Latest Quote
$18.35
-0.37 (-1.98%)
Current Price
| Previous Close | $18.72 |
| Open | $18.50 |
| Day High | $18.50 |
| Day Low | $18.35 |
| Volume | 8,088 |
Stock Information
| Shares Outstanding | 48.03M |
| Total Debt | $26.13M |
| Cash Equivalents | $175.75M |
| Revenue | $1.06M |
| Net Income | $-148.47M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $881.37M |
| EPS (TTM) | $-3.15 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.45B |
| Sales | $1.06M |
| Income | $-148.47M |
| Book/sh | $-211.05 |
| Cash/sh | $3.66 |
| Employees | 100 |
Financial Ratios
| Quick Ratio | 7.91 |
| Current Ratio | 8.33 |
| Debt/Eq | 14.53 |
Returns & Margins
| Operating Margin | -14232.42% |
Ownership
| Insider Ownership | 1.93% |
| Institutional Ownership | 47.51% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.73 |
| P/S | 833.06 |
| P/B | -0.09 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $32.00 |
Technical Indicators
| SMA20 | $17.40 |
| RSI | 61.23 |
| ATR | 1.1786 |
| Shares Float | 25.66M |
| Short Float | 1.25% |
| Short Ratio | 0.97 |
| Rel Volume | 0.02 |
Performance History
| Week | +3.97% |
| Month | +3.44% |
| YTD | +11.75% |
| 10 Years | +11.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $18.35 | 8,088 |
| 2026-06-22 | $18.72 | 376,000 |
| 2026-06-18 | $19.07 | 1,602,900 |
| 2026-06-17 | $18.48 | 471,200 |
| 2026-06-16 | $17.87 | 451,900 |
| 2026-06-15 | $17.65 | 278,300 |
| 2026-06-12 | $16.90 | 250,400 |
| 2026-06-11 | $16.81 | 214,700 |
| 2026-06-10 | $16.20 | 422,000 |
| 2026-06-09 | $17.09 | 269,300 |
| 2026-06-08 | $17.12 | 197,800 |
| 2026-06-05 | $16.43 | 389,800 |
| 2026-06-04 | $17.00 | 200,500 |
| 2026-06-03 | $16.69 | 365,100 |
| 2026-06-02 | $16.93 | 451,200 |
| 2026-06-01 | $16.96 | 127,400 |
| 2026-05-29 | $17.01 | 165,300 |
| 2026-05-28 | $17.92 | 309,200 |
| 2026-05-27 | $17.19 | 405,100 |
| 2026-05-26 | $17.56 | 400,100 |
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorÂassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,976,000 | $4,472,000 | $1,037,000 | $0 |
| Operating Revenue | $2,976,000 | $4,472,000 | $1,037,000 | $0 |
| Expenses | ||||
| Interest Expense | $17,000 | $18,000 | $335,000 | $291,000 |
| Total Expenses | $164,132,000 | $139,695,000 | $134,476,000 | $122,776,000 |
| Other Income Expense | $5,251,000 | $-2,100,000 | $-509,000 | $-5,175,000 |
| Other Non Operating Income Expenses | $1,204,000 | $-302,000 | $-212,000 | $-47,000 |
| Net Non Operating Interest Income Expense | $6,331,000 | $8,471,000 | $8,457,000 | $3,633,000 |
| Interest Expense Non Operating | $17,000 | $18,000 | $335,000 | $291,000 |
| Operating Expense | $164,132,000 | $139,695,000 | $134,476,000 | $122,776,000 |
| General And Administrative Expense | $37,516,000 | $27,116,000 | $22,197,000 | $21,021,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-148,647,000 | $-129,321,000 | $-125,938,000 | $-124,665,000 |
| Net Interest Income | $6,331,000 | $8,471,000 | $8,457,000 | $3,633,000 |
| Interest Income | $6,348,000 | $8,489,000 | $8,792,000 | $3,924,000 |
| Normalized Income | $-152,669,718 | $-127,900,580 | $-125,703,370 | $-120,613,880 |
| Net Income From Continuing And Discontinued Operation | $-148,647,000 | $-129,321,000 | $-125,938,000 | $-124,665,000 |
| Total Operating Income As Reported | $-157,109,000 | $-137,021,000 | $-133,736,000 | $-127,904,000 |
| Net Income Common Stockholders | $-148,647,000 | $-130,401,000 | $-130,920,000 | $-124,665,000 |
| Net Income | $-148,647,000 | $-129,321,000 | $-125,938,000 | $-124,665,000 |
| Net Income Including Noncontrolling Interests | $-148,647,000 | $-129,321,000 | $-125,938,000 | $-124,665,000 |
| Net Income Continuous Operations | $-148,647,000 | $-129,321,000 | $-125,938,000 | $-124,665,000 |
| Pretax Income | $-149,574,000 | $-128,852,000 | $-125,491,000 | $-124,318,000 |
| Special Income Charges | $4,047,000 | $-1,798,000 | $-297,000 | $-5,128,000 |
| Interest Income Non Operating | $6,348,000 | $8,489,000 | $8,792,000 | $3,924,000 |
| Operating Income | $-161,156,000 | $-135,223,000 | $-133,439,000 | $-122,776,000 |
| Per Share | ||||
| Diluted EPS | $-5.39 | $-4.73 | $-1.32 | $-4.52 |
| Basic EPS | $-5.39 | $-4.73 | $-1.32 | $-4.52 |
| Other | ||||
| Tax Effect Of Unusual Items | $24,282 | $-377,580 | $-62,370 | $-1,076,880 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-148,693,000 | $-121,843,000 | $-119,951,000 | $-116,135,000 |
| Total Unusual Items | $4,047,000 | $-1,798,000 | $-297,000 | $-5,128,000 |
| Total Unusual Items Excluding Goodwill | $4,047,000 | $-1,798,000 | $-297,000 | $-5,128,000 |
| Reconciled Depreciation | $4,911,000 | $5,193,000 | $4,908,000 | $2,764,000 |
| EBITDA (Bullshit earnings) | $-144,646,000 | $-123,641,000 | $-120,248,000 | $-121,263,000 |
| EBIT | $-149,557,000 | $-128,834,000 | $-125,156,000 | $-124,027,000 |
| Diluted Average Shares | $27,561,183 | $27,561,183 | $99,234,758 | $27,561,183 |
| Basic Average Shares | $27,561,183 | $27,561,183 | $99,234,758 | $27,561,183 |
| Diluted NI Availto Com Stockholders | $-148,647,000 | $-130,401,000 | $-130,920,000 | $-124,665,000 |
| Tax Provision | $-927,000 | $469,000 | $447,000 | $347,000 |
| Restructuring And Mergern Acquisition | $-4,047,000 | $1,798,000 | $297,000 | $5,128,000 |
| Research And Development | $126,616,000 | $112,579,000 | $112,279,000 | $101,755,000 |
| Selling General And Administration | $37,516,000 | $27,116,000 | $22,197,000 | $21,021,000 |
| Other Gand A | $16,866,000 | $12,715,000 | $8,883,000 | $10,454,000 |
| Salaries And Wages | $20,650,000 | $14,401,000 | $13,314,000 | $10,567,000 |
| Preferred Stock Dividends | - | $1,080,000 | $4,982,000 | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-502,867,000 | $-396,443,000 | $-277,172,000 | $-158,678,000 |
| Total Assets | $269,788,000 | $197,435,000 | $286,521,000 | $317,150,000 |
| Total Non Current Assets | $79,132,000 | $61,925,000 | $93,985,000 | $68,438,000 |
| Other Non Current Assets | $3,332,000 | $8,539,000 | $3,686,000 | $1,606,000 |
| Investmentin Financial Assets | $35,198,000 | $0 | $29,102,000 | $0 |
| Goodwill And Other Intangible Assets | $14,589,000 | $13,916,000 | $14,464,000 | $14,058,000 |
| Other Intangible Assets | $262,000 | $570,000 | $910,000 | $1,179,000 |
| Current Assets | $190,656,000 | $135,510,000 | $192,536,000 | $248,712,000 |
| Other Current Assets | $9,298,000 | $6,156,000 | $5,539,000 | $7,669,000 |
| Cash Cash Equivalents And Short Term Investments | $181,358,000 | $129,354,000 | $186,997,000 | $241,043,000 |
| Cash And Cash Equivalents | $41,687,000 | $59,136,000 | $52,545,000 | $241,043,000 |
| Debt | ||||
| Total Debt | $27,111,000 | $31,006,000 | $34,380,000 | $42,490,000 |
| Long Term Debt And Capital Lease Obligation | $21,900,000 | $26,430,000 | $30,523,000 | $39,137,000 |
| Current Debt And Capital Lease Obligation | $5,211,000 | $4,576,000 | $3,857,000 | $3,353,000 |
| Long Term Debt | - | - | - | $4,759,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $758,066,000 | $579,962,000 | $549,229,000 | $461,770,000 |
| Total Non Current Liabilities Net Minority Interest | $731,591,000 | $551,547,000 | $527,142,000 | $438,973,000 |
| Other Non Current Liabilities | $6,133,000 | $10,224,000 | $8,414,000 | $8,202,000 |
| Current Liabilities | $26,475,000 | $28,415,000 | $22,087,000 | $22,797,000 |
| Other Current Liabilities | $374,000 | $753,000 | - | - |
| Current Deferred Liabilities | $64,000 | $6,768,000 | $406,000 | $1,000,000 |
| Payables And Accrued Expenses | $14,123,000 | $10,144,000 | $10,350,000 | $11,991,000 |
| Payables | $7,872,000 | $6,319,000 | $7,906,000 | $8,599,000 |
| Accounts Payable | $7,872,000 | $6,319,000 | $7,729,000 | $8,051,000 |
| Total Tax Payable | - | - | $177,000 | $548,000 |
| Equity | ||||
| Common Stock Equity | $-488,278,000 | $-382,527,000 | $-262,708,000 | $-144,620,000 |
| Total Equity Gross Minority Interest | $-488,278,000 | $-382,527,000 | $-262,708,000 | $-144,620,000 |
| Stockholders Equity | $-488,278,000 | $-382,527,000 | $-262,708,000 | $-144,620,000 |
| Gains Losses Not Affecting Retained Earnings | $245,000 | $-1,341,000 | $-858,000 | $-2,183,000 |
| Other Equity Adjustments | $245,000 | $-1,341,000 | $-858,000 | $-2,183,000 |
| Retained Earnings | $-568,139,000 | $-419,492,000 | $-289,091,000 | $-158,171,000 |
| Preferred Securities Outside Stock Equity | $703,558,000 | $514,893,000 | $488,205,000 | $391,634,000 |
| Other | ||||
| Ordinary Shares Number | $47,174,156 | $47,174,156 | $47,174,156 | $47,174,156 |
| Share Issued | $47,174,156 | $47,174,156 | $47,174,156 | $47,174,156 |
| Tangible Book Value | $-502,867,000 | $-396,443,000 | $-277,172,000 | $-158,678,000 |
| Invested Capital | $-488,278,000 | $-382,527,000 | $-262,708,000 | $-139,861,000 |
| Working Capital | $164,181,000 | $107,095,000 | $170,449,000 | $225,915,000 |
| Capital Lease Obligations | $27,111,000 | $31,006,000 | $34,380,000 | $37,731,000 |
| Total Capitalization | $-488,278,000 | $-382,527,000 | $-262,708,000 | $-139,861,000 |
| Additional Paid In Capital | $79,616,000 | $38,306,000 | $27,240,000 | $15,733,000 |
| Capital Stock | $0 | $0 | $1,000 | $1,000 |
| Common Stock | $0 | $0 | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $21,900,000 | $26,430,000 | $30,523,000 | $34,378,000 |
| Current Deferred Revenue | $0 | $2,877,000 | $406,000 | $1,000,000 |
| Current Capital Lease Obligation | $5,211,000 | $4,576,000 | $3,857,000 | $3,353,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,703,000 | $6,174,000 | $7,474,000 | $6,453,000 |
| Current Accrued Expenses | $6,251,000 | $3,825,000 | $2,444,000 | $3,392,000 |
| Investments And Advances | $35,198,000 | $0 | $29,102,000 | $0 |
| Available For Sale Securities | $35,198,000 | - | $29,102,000 | - |
| Goodwill | $14,327,000 | $13,346,000 | $13,554,000 | $12,879,000 |
| Net PPE | $26,013,000 | $39,470,000 | $46,733,000 | $52,774,000 |
| Accumulated Depreciation | $-14,160,000 | $-11,424,000 | $-6,859,000 | $-2,449,000 |
| Gross PPE | $40,173,000 | $50,894,000 | $53,592,000 | $55,223,000 |
| Leases | $501,000 | $306,000 | $272,000 | $206,000 |
| Other Properties | $37,957,000 | $48,961,000 | $51,699,000 | $53,769,000 |
| Machinery Furniture Equipment | $1,715,000 | $1,627,000 | $1,621,000 | $1,248,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $139,671,000 | $70,218,000 | $134,452,000 | $0 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-130,700,000 | $-118,235,000 | $-117,784,000 | $-112,869,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-129,468,000 | $-117,471,000 | $-112,728,000 | $-99,842,000 |
| Cash Flow From Continuing Operating Activities | $-129,468,000 | $-117,471,000 | $-112,728,000 | $-99,842,000 |
| Operating Gains Losses | $1,361,000 | $4,000 | $54,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,232,000 | $-764,000 | $-5,056,000 | $-13,027,000 |
| Investing Cash Flow | $-103,943,000 | $96,784,000 | $-165,020,000 | $-13,027,000 |
| Cash Flow From Continuing Investing Activities | $-103,943,000 | $96,784,000 | $-165,020,000 | $-13,027,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $212,458,000 | $27,477,000 | $96,571,000 | $177,765,000 |
| Financing Cash Flow | $215,646,000 | $26,979,000 | $92,076,000 | $182,717,000 |
| Cash Flow From Continuing Financing Activities | $215,646,000 | $26,979,000 | $92,076,000 | $182,717,000 |
| Net Preferred Stock Issuance | $212,458,000 | $27,477,000 | $96,571,000 | $177,765,000 |
| Preferred Stock Issuance | $212,458,000 | $27,477,000 | $96,571,000 | $177,765,000 |
| Net Other Financing Charges | - | $-1,008,000 | - | - |
| Other | ||||
| Interest Paid Supplemental Data | $10,000 | $18,000 | $156,000 | $291,000 |
| Income Tax Paid Supplemental Data | $260,000 | $495,000 | $319,000 | $0 |
| End Cash Position | $44,897,000 | $62,346,000 | $56,004,000 | $241,671,000 |
| Beginning Cash Position | $62,346,000 | $56,004,000 | $241,671,000 | $171,846,000 |
| Effect Of Exchange Rate Changes | $316,000 | $50,000 | $5,000 | $-23,000 |
| Changes In Cash | $-17,765,000 | $6,292,000 | $-185,672,000 | $69,848,000 |
| Proceeds From Stock Option Exercised | $3,188,000 | $510,000 | $264,000 | $76,000 |
| Net Investment Purchase And Sale | $-103,068,000 | $97,548,000 | $-159,988,000 | $0 |
| Sale Of Investment | $105,900,000 | $150,159,000 | $78,124,000 | $0 |
| Purchase Of Investment | $-208,968,000 | $-52,611,000 | $-238,112,000 | $0 |
| Net PPE Purchase And Sale | $-875,000 | $-764,000 | $-5,032,000 | $-13,027,000 |
| Sale Of PPE | $357,000 | $0 | $24,000 | $0 |
| Purchase Of PPE | $-1,232,000 | $-764,000 | $-5,056,000 | $-13,027,000 |
| Change In Working Capital | $-4,728,000 | $-3,307,000 | $896,000 | $-544,000 |
| Change In Other Current Liabilities | $-4,598,000 | $-3,903,000 | $-3,207,000 | $-7,796,000 |
| Change In Other Current Assets | $5,162,000 | $-217,000 | $758,000 | $-472,000 |
| Change In Payables And Accrued Expense | $-2,087,000 | $1,432,000 | $1,160,000 | $10,144,000 |
| Change In Accrued Expense | $-4,148,000 | $3,130,000 | $-1,084,000 | $6,876,000 |
| Change In Payable | $2,061,000 | $-1,698,000 | $2,244,000 | $3,268,000 |
| Change In Account Payable | $2,061,000 | $-1,698,000 | $2,244,000 | $3,268,000 |
| Change In Prepaid Assets | $-3,205,000 | $-619,000 | $2,185,000 | $-2,420,000 |
| Other Non Cash Items | $-606,000 | $5,730,000 | $4,354,000 | $17,086,000 |
| Stock Based Compensation | $14,322,000 | $8,686,000 | $6,261,000 | $5,517,000 |
| Asset Impairment Charge | $5,440,000 | $0 | - | - |
| Amortization Of Securities | $-1,521,000 | $-4,456,000 | $-3,263,000 | $0 |
| Depreciation Amortization Depletion | $4,911,000 | $5,193,000 | $4,908,000 | $2,764,000 |
| Depreciation And Amortization | $4,911,000 | $5,193,000 | $4,908,000 | $2,764,000 |
| Gain Loss On Sale Of PPE | $1,361,000 | $4,000 | $54,000 | $0 |
| Net Income From Continuing Operations | $-148,647,000 | $-129,321,000 | $-125,938,000 | $-124,665,000 |
| Depreciation | - | $5,100,000 | - | - |
| Net Issuance Payments Of Debt | - | - | $-4,759,000 | $4,876,000 |
| Net Long Term Debt Issuance | - | - | $-4,759,000 | $4,876,000 |
Fetched: 2026-06-20